Additionally, to overcome the potential infection problems associated with the clinical use of blood products, PHSRN—a peptide corresponding to the second cell-binding domain of fibronectin—was developed as an alternative to blood-derived fibronectin eye drops24. This evidence concerns the gene FN1 and infection.